November 19, 2026
Thymosin Beta-4 Eye Drop RGN-259 Misses Its Primary Endpoint in a Third Phase 3 Trial
RGN-259, an eye drop of the peptide thymosin beta-4, did not reach statistical significance on its primary endpoint in SEER-2, a phase 3 trial in neurotrophic keratopathy, its developers announced in November 2026. It is the third phase 3 trial of the eye drop for this condition, and none has met its primary endpoint. No healing rates have been published yet.
What was announced
HLB Therapeutics announced topline results from SEER-2, a phase 3 trial of RGN-259 for neurotrophic keratopathy (NK), a condition in which the cornea loses its nerve supply and heals poorly. The trial was run by ReGenTree, a joint venture between HLB Therapeutics and RegeneRx BioPharmaceuticals. RegeneRx reproduced the announcement in full in a letter to its stockholders dated November 16, 2026[1]. According to the announcement, HLB received the topline results from the contract research organization on November 13, and “the trial did not achieve statistical significance in the primary endpoint, defined as the difference in complete healing rates between the RGN-259 treatment group and the placebo group after 4 weeks of treatment”[1].
The announcement gives no healing rates, no p-value and no safety findings, so none is reported here.
The trial
SEER-2 enrolled patients at 50 medical institutions: 41 hospitals in the US and 9 in Italy, Spain and Poland. Treatment and patient follow-up had concluded by September 1, 2026[2]. RegeneRx had described its enrolment goal as 70 patients in the US arm[3]; the final number randomized has not been published.
Three phase 3 trials
| Trial | Where | Primary endpoint |
|---|---|---|
| SEER-1 | US, 18 patients | Not met (p = 0.0656). Complete healing at 4 weeks in 6 of 10 on RGN-259 vs 1 of 8 on placebo[4] |
| SEER-3 | Europe | Not met, as RegeneRx reported[3] |
| SEER-2 | US and Europe, 50 sites | Not met, topline November 2026; rates not yet published[1][2] |
In SEER-1, the published trial, its authors wrote that the primary endpoint “was not met with statistical significance (p = 0.0656) but showed a strong efficacy trend,” and that 16 adverse events occurred across seven of the 18 patients[4].
What RGN-259 is, and is not
RGN-259 is a sterile, preservative-free eye drop of thymosin beta-4, a natural 43-amino-acid peptide. It is not TB-500, the research-market peptide sold under that name, which is a seven-amino-acid fragment of thymosin beta-4; how the two differ is set out in TB-500 vs thymosin beta-4. Results for an eye drop of the full protein say nothing about injected TB-500. No thymosin beta-4 product is approved by FDA.
For the human evidence on the injected peptides people buy as research compounds, see the orthopaedic review of BPC-157 and TB-500.
What comes next
The developers say they expect the complete data from the contract research organization “in the coming weeks,” will then analyze the primary and secondary endpoints and subgroups, and will “carefully review its future development direction and plans”[1].
Sources
- RegeneRx BioPharmaceuticals. Letter to stockholders, November 16, 2026, reproducing HLB Therapeutics’ announcement of the SEER-2 topline results in full. regenerx.com
- RegeneRx BioPharmaceuticals. Letter to stockholders, September 1, 2026: SEER-2 completed; 50 sites (41 US, 9 in Italy, Spain and Poland). regenerx.com
- RegeneRx BioPharmaceuticals. Letter to stockholders, May 6, 2026: SEER-3 in the EU did not meet the primary endpoints; SEER-2 enrolment goal of 70 patients in the US. regenerx.com
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. PMID 36613994. SEER-1, NCT02600429. PMC9820614
Checked and updated
